Skip to main content
  • Letter to the Editor
  • Open access
  • Published:

COVID-19 biomarkers for severity mapped to polycystic ovary syndrome

A Correction to this article was published on 15 March 2021

This article has been updated

To the Editor,

Large scale multi-omics analysis has identified significant differences in the biomarkers between COVID-19 disease and control subjects [1]. These protein panels target biological processes involved in vessel damage, platelet degranulation, the coagulation cascade and the acute phase response [1], with greater protein changes dependent on the COVID-19 severity. However, it is observed that in metabolic conditions such as polycystic ovary syndrome expressed proteins differ compared to control women [2] and PCOS patients have increased platelet aggregation and decreased plasma fibrinolytic activity, resulting in a prothrombotic propensity [3, 4], with elevated coagulation markers [5]. Therefore, any biomarkers reflecting COVID-19 disease and its severity would necessarily have to be independent of differentially-expressed proteins relating to other conditions; therefore, this proteomic analysis was undertaken in women with and without PCOS to compare with the proteomic biomarkers recently described in COVID-19 using shotgun proteomics followed by parallel reaction monitoring [1].

146 PCOS and 97 control women who presented sequentially to the Department of Endocrinology, Hull and East Yorkshire Hospitals NHS Trust were recruited to the local PCOS biobank (ISRCTN70196169) [2]. PCOS diagnosis was based on all three Rotterdam consensus diagnostic criteria. Proteins that were identified as being altered in COVID-19 disease for vessel damage (16 proteins), platelet degranulation (11 proteins), coagulation cascade (24 proteins) and acute phase response (9 proteins), shown in Table 1, were determined by Slow Off-rate Modified Aptamer (SOMA)-scan plasma protein measurement [6]. Statistics were performed using Graphpad Prism 8.0.

Table 1 Proteins identified as being altered in COVID-19 disease categorized according to biological processes: vessel damage (16 proteins), platelet degranulation (11 proteins), coagulation cascade (24 proteins) and acute phase response (9 proteins) in PCOS and control women

As reported previously [2], cohorts were age-matched, but PCOS women had increased insulin resistance, androgens and CRP (p < 0.001): systolic and diastolic blood pressure, and waist circumference were higher (p < 0.05).

For the 60 protein biomarkers described previously, 21 were found to differ in PCOS: for vessel damage 7 of 16 proteins differed, for platelet degranulation 2 of 11 proteins differed, for the coagulation cascade 9 of 24 proteins differed and for the acute phase response 3 of 9 proteins differed (Table 1).

These data show that altered protein expression relative to controls may occur in other conditions such as PCOS, and that COVID-19 biomarker changes found between respiratory patients with and without COVID-19 require validation before they can be confirmed to be related to COVID-19 disease and its severity. It is of concern that a number of significant protein biomarkers described for COVID-19 patients and its severity were also found in PCOS, spanning the biological processes involved in vessel damage, platelet degranulation, the coagulation cascade and the acute phase response, perhaps indicating why these patients may be at risk of more severe COVID-19 disease [7].

Limitations of the study include utilizing a different method of proteomic analysis compared to others that may not be directly comparable [1].

In conclusion, 21 of 60 protein biomarkers reported in respiratory patients with COVID-19 were found to differ between women with and without PCOS, showing the necessity for validation of such biomarkers, and suggesting that more severe COVID-19 disease may occur in PCOS.

Availability of data and materials

All the data for this study will be made available upon reasonable request to the corresponding author.

Change history


  1. Overmyer KA, Shishkova E, Miller IJ, Balnis J, Bernstein MN, Peters-Clarke TM, et al. Large-Scale Multi-omic Analysis of COVID-19 Severity. Cell Syst. 2020.

    Article  PubMed  PubMed Central  Google Scholar 

  2. Moin ASM, Sathyapalan T, Atkin SL, Butler AE. Renin-Angiotensin System Overactivation in Polycystic Ovary Syndrome, a Risk for SARS-CoV-2 Infection? Metabol Open. 2020;7:100052.

    Article  Google Scholar 

  3. Mak W, Dokras A. Polycystic ovarian syndrome and the risk of cardiovascular disease and thrombosis. Semin Thromb Hemost. 2009;35(7):613–20.

    Article  CAS  Google Scholar 

  4. Yildiz BO, Haznedaroğlu IC, Kirazli S, Bayraktar M. Global fibrinolytic capacity is decreased in polycystic ovary syndrome, suggesting a prothrombotic state. J Clin Endocrinol Metabol. 2002;87(8):3871–5.

    Article  CAS  Google Scholar 

  5. Oral B, Mermi B, Dilek M, Alanoğlu G, Sütçü R. Thrombin activatable fibrinolysis inhibitor and other hemostatic parameters in patients with polycystic ovary syndrome. Gynecol Endocrinol. 2009;25(2):110–6.

    Article  CAS  Google Scholar 

  6. Kahal H, Halama A, Aburima A, Bhagwat AM, Butler AE, Grauman J, et al. Effect of induced hypoglycemia on inflammation and oxidative stress in type 2 diabetes and control subjects. Sci Rep. 2020;10(1):4750.

    Article  CAS  Google Scholar 

  7. Juusela A, Nazir M, Gimovsky M. Two cases of coronavirus 2019-related cardiomyopathy in pregnancy. Am J Obstet Gynecol MFM. 2020;2(2):100113.

    Article  Google Scholar 

Download references




No funding was received to perform this study.

Author information

Authors and Affiliations



ASMM and AEB analyzed the data and wrote the manuscript. TS supervised clinical studies and edited the manuscript. SLA contributed to study design, data interpretation and the writing of the manuscript. AEB is the guarantor of this work. All authors read and approved the final manuscript.

Corresponding author

Correspondence to Alexandra E. Butler.

Ethics declarations

Ethics approval and consent to participate

The Newcastle & North Tyneside Ethics committee approved this study that was conducted according to the Declaration of Helsinki. All study participants signed an informed consent form prior to participation.

Consent for publication

All authors gave their consent for publication.

Competing interests

No authors have any conflict of interest or competing interests to declare.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Moin, A.S.M., Sathyapalan, T., Atkin, S.L. et al. COVID-19 biomarkers for severity mapped to polycystic ovary syndrome. J Transl Med 18, 490 (2020).

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: